3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Head and Neck Neoplasms
2103
Squamous Cell Carcinoma of Head and Neck
1654
Nasopharyngeal Carcinoma
517
Thyroid Neoplasms
478
Carcinoma, Non-Small-Cell Lung
438
Breast Neoplasms
315
Mouth Neoplasms
312
Neoplasms
309
Melanoma
299
Oropharyngeal Neoplasms
285
Colorectal Neoplasms
274
Lung Neoplasms
248
Carcinoma, Squamous Cell
240
Neoplasm Metastasis
235
Ovarian Neoplasms
228
Uterine Cervical Neoplasms
204
Stomach Neoplasms
195
Salivary Gland Neoplasms
192
Laryngeal Neoplasms
192
Nasopharyngeal Neoplasms
189
Carcinoma, Renal Cell
183
Esophageal Neoplasms
179
Pancreatic Neoplasms
176
Prostatic Neoplasms
158
Sarcoma
142
Triple Negative Breast Neoplasms
136
Urinary Bladder Neoplasms
135
Recurrence
128
Endometrial Neoplasms
124
Hypopharyngeal Neoplasms
121
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Head & Neck
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled